News | November 10, 2025
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The submission is supported by results from the Phase 3b APEX study
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Subscribe To Our Newsletter & Stay Updated
